Literature DB >> 9684798

Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver.

D Cain1, S M Hutson, R Wallin.   

Abstract

Warfarin, the most used drug in the world in long-term anticoagulation prophylaxis, targets the vitamin K 2,3-epoxide reductase (VKOR) of the vitamin K cycle in liver. Recently, the enzyme has been identified as a multicomponent lipid-protein enzyme system in the endoplasmic reticulum (ER) membrane (17). As the first step towards understanding genetic resistance to warfarin, we present in this paper data on VKOR from normal and a strain of warfarin resistant laboratory rats maintained in the United States. Metal induced in vitro assembly of the enzyme complex demonstrates that the glutathione-S-transferase (GST) enzyme component of the complex loses its GST activity upon formation of VKOR. Less VKOR activity is measured upon assembly of the complex from warfarin resistant rats. The GST activity measured in warfarin resistant rats, before assembly of the complex, is 10-fold less sensitive to warfarin inhibition than the GST activity measured in normal rats. Microsomal epoxide hydrolase (mEH) is the second component of VKOR. When incubated with the components of VKOR before assembly of the complex, antibodies raised against mEH prevented formation of the enzyme complex. Sequencing of mEH cDNAs from normal and warfarin resistant rats revealed identical sequences. The data suggest that the mutation responsible for genetic warfarin resistance is associated with the GST component of VKOR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684798

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

Review 1.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  The genetic basis of resistance to anticoagulants in rodents.

Authors:  Hans-Joachim Pelz; Simone Rost; Mirja Hünerberg; Andreas Fregin; Ann-Charlotte Heiberg; Kristof Baert; Alan D MacNicoll; Colin V Prescott; Anne-Sophie Walker; Johannes Oldenburg; Clemens R Müller
Journal:  Genetics       Date:  2005-05-06       Impact factor: 4.562

3.  Detecting species-site dependencies in large multiple sequence alignments.

Authors:  Roland Schwarz; Philipp N Seibel; Sven Rahmann; Christoph Schoen; Mirja Huenerberg; Clemens Müller-Reible; Thomas Dandekar; Rachel Karchin; Jörg Schultz; Tobias Müller
Journal:  Nucleic Acids Res       Date:  2009-08-06       Impact factor: 16.971

Review 4.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Locus-specific genetic differentiation at Rw among warfarin-resistant rat (Rattus norvegicus) populations.

Authors:  Michael H Kohn; Hans-Joachim Pelz; Robert K Wayne
Journal:  Genetics       Date:  2003-07       Impact factor: 4.562

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.